{"id":"NCT03402386","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan","officialTitle":"A Phase III, Open-label Study of MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-01-03","primaryCompletion":"2018-11-22","completion":"2018-12-20","firstPosted":"2018-01-18","resultsPosted":"2021-07-06","lastUpdate":"2023-12-28"},"enrollment":42,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anemia; Peritoneal Dialysis Dependent Chronic Kidney Disease"],"interventions":[{"type":"DRUG","name":"MT-6548","otherNames":["vadadustat","AKB-6548"]}],"arms":[{"label":"MT-6548","type":"EXPERIMENTAL"}],"summary":"To evaluate the efficacy and safety of MT-6548 in peritoneal dialysis subjects with anemia associated with chronic kidney disease","primaryOutcome":{"measure":"Mean Hb Level of Week 20 and Week 24","timeFrame":"Up to Week 24","effectByArm":[{"arm":"MT-6548","deltaMin":11.35,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":16},"locations":{"siteCount":17,"countries":["Japan"]},"refs":{"pmids":["33283981"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":42},"commonTop":["Catheter site infection","Diarrhoea","Nasopharyngitis","Vomiting","Abdominal pain upper"]}}